Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia

Pappalardi, M. B.; Keenan, K.; Cockerill, Mark; Kellner, W. A.; Stowell, Alexandra; Sherk, C.; Wong, K.; Pathuri, S.; Briand, J.; Steidel, M.; Chapman, Philip; Groy, A.; Wiseman, A. K.; McHugh, C. F.; Campobasso, N.; Graves, A. P.; Fairweather, E.; Werner, T.; Raoof, Ali; Butlin, Roger J; Rueda, L.; Horton, J. R.; Fosbenner, D. T.; Zhang, C.; Handler, J. L.; Muliaditan, M.; Mebrahtu, M.; Jaworski, J. P.; McNulty, D. E.; Burt, Charlotte; Eberl, H. C.; Taylor, A. N.; Ho, T.; Merrihew, S.; Foley, S. W.; Rutkowska, A.; Li, M.; Romeril, S. P.; Goldberg, Kristin; Zhang, X.; Kershaw, Christopher S; Bantscheff, M.; Jurewicz, A. J.; Minthorn, E.; Grandi, P.; Patel, M.; Benowitz, A. B.; Mohammad, H. P.; Gilmartin, A. G.; Prinjha, R. K.; Ogilvie, Donald; Carpenter, C.; Heerding, D.; Baylin, S. B.; Jones, P. A.; Cheng, X.; King, B. W.; Luengo, J. I.; Jordan, Allan M; Waddell, Ian D; Kruger, R. G.; McCabe, M. T.

Affiliation

Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA

Issue Date

2021

Metadata

Show full item record

Citation

Pappalardi MB, Keenan K, Cockerill M, Kellner WA, Stowell A, Sherk C, et al. Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. Nat Cancer. 2021;2(10):1002-17.

Journal

Nature Cancer

URI

http://hdl.handle.net/10541/624970

PubMed ID

34790902

Type

Article

Collections

All Paterson Institute for Cancer Research